Refers to a compound of formula I, where one of A1, A2, A3, A4, A7, A8, A9 and A10 is N and the remaining C A5 is NR5, S r1 to R10 are each h, halogeno, cyano, heterocicloalquilo 4 - 10 members replaced or not R2 is H, alkyl C8 alquenilo C1 - C2, C8, halogeno, cyano, among others R3 is H, C1 to C8 alkyl - substituted or not with one or more halogens, 1 or more Oh, aryl C6 C10, cyano,Among others R4 is H, alkyl C8 cycloalkyl - C1 - C3, C8, cyano, hidroxicarbonilo, hydroxyl, among others R5 is H, alkyl C8 alquilsulfonilo C1, C1 - C2 C8 C8, alquinilo, among others and r6 R6 are each alkyl C8 alquenilo C1 - C2, C8 or cycloalkyl together form C3, C8, hterocicloalquilo 4 - 10 Members replaced or not, among others R7 is H, halogen, alkoxyl alquilsulfonilo C1 C1 C8 C8Nitro, among others R8 is H, alkyl C1 C8 substituted or unsubstituted cycloalkyl, alquenilo C2 C8 C8 alcoxicarbonilo C1 - C3, C8, Oxo, cyano, among others R9 is H, alkyl C8 alquinilo C1, C2 - C3 - C8 C8, cycloalkyl, halogen, among others. A Preferred Compound is: 9 - (4 - isopropyl - piperazin-1-yl) - 6.6 - dimethyl - 11 oxo - 3.8 - dihydro - 5h benzo [b] - 3 - carbonitrilo carbazole.These compounds are of ALK inhibitors useful in the treatment of cancer, metastasis, depressionREFERIDA A UN COMPUESTO DE FORMULA I, DONDE UNO DE A1, A2, A3, A4, A7, A8, A9 Y A10 ES N Y LOS RESTANTES C A5 ES NR5, O, S R1 Y R10 SON CADA UNO H, CIANO, HALOGENO, HETEROCICLOALQUILO DE 4-10 MIEMBROS SUSTITUIDO O NO R2 ES H, ALQUILO C1-C8, ALQUENILO C2-C8, CIANO, HALOGENO, ENTRE OTROS R3 ES H, ALQUILO C1-C8 SUSTITUIDO O NO CON 1 O MAS HALOGENOS, 1 O MAS OH, ARILO C6-C10, CIANO, ENTRE OTROS R4 ES H, ALQUILO C1-C8, CICLOALQUILO C3-C8, CIANO, HIDROXICARBONILO, HIDROXILO, ENTRE OTROS R5 ES H, ALQUILO C1-C8, ALQUILSULFONILO C1-C8, ALQUINILO C2-C8, ENTRE OTROS R6 Y R6 SON CADA UNO ALQUILO C1-C8, ALQUENILO C2-C8, O JUNTOS FORMAN CICLOALQUILO C3-C8, HTEROCICLOALQUILO DE 4-10 MIEMBROS SUSTITUIDO O NO, ENTE OTROS R7 ES H, HALOGENO, ALCOXILO C1-C8,
